CPHI India

informa markets

Peptide
Therapeutics Summit

11th November 2025

Radisson Blu Plaza Hotel, Banjara Hills, Hyderabad

Advancing Therapeutics Through
Peptide Innovation Transforming Medicine



ABOUT THE CONFERENCE

India is fast becoming a global hub for advanced biologics and precision therapeutics with peptide therapy at the heart of this transformation. The Peptide Therapeutics Summit 2025 is a focused, one-day strategic forum bringing together leading scientists, regulatory authorities, manufacturers, and industry innovators to explore the latest breakthroughs and pressing challenges in peptide-based drug development.

Designed to ignite meaningful dialogue and drive actionable insights, this summit will cover the entire peptide therapeutics value chain—from early-stage research to large-scale commercialization. Key discussions will dive into critical areas such as regulatory navigation, formulation development, and the transition from gram-scale to kilogram-scale production.

With sessions led by domain experts, the conference will address: The challenges of bringing novel therapeutic modalities to market, Choosing the optimal path for scalable, cost-effective manufacturing, Overcoming formulation development hurdles and Strategies for successful scale-up and regulatory approval.

Tailored for professionals working across the peptide therapeutics ecosystem, this event offers fresh regulatory intelligence, practical tools for compliance, and forward-thinking strategies to accelerate innovation while ensuring patient safety.

INDUSTRY OVERVIEW

The peptide therapeutics market in India is expected to reach a projected revenue of US$ 2,265.8 million by 2030. A compound annual growth rate of 13.8% is expected of India peptide therapeutics market from 2024 to 2030.

The India peptide therapeutics market generated a revenue of USD 984.7 million in 2023 and is expected to reach USD 2,265.8 million by 2030. The India market is expected to grow at a CAGR of 12.6% from 2024 to 2030. In terms of segment, metabolic disorders was the largest revenue generating application in 2023. Metabolic disorders is the most lucrative application segment registering the fastest growth during the forecast period followed by oncology, cardiovascular diseases, infectious diseases, pain management and more.

INDUSTRY GROWTH

India Peptide therapeutics market, 2018-2030 (US$M)



WHY ATTEND

- 20+ Expert Speakers
- Networking opportunity with 50+ people from the peptides industry
- Expert opinion from the best of the industry on the prospects and the Latest Developments in the industry will be discussed
- Exhibitors providing Innovative Solutions for the industry



WHO SHOULD ATTEND

DEPARTMENT

- Research and Development (R&D)
- Drug Discovery and Development
- Manufacturing & Process Development
- Quality Assurance & Quality Control
- Researchers and Scientists
- Analytical Development
- Pharmaceutical and Biotech Industry Professionals
- Regulatory and Compliance Experts



WHY PARTNER

- One of its kind of platforms with key focus on from a 360-degree approach.
- An opportunity to connect with more than 50+ peptides industry professionals.
- Top speakers from the industry majorly the Directors, Presidents, VPs of top peptides companies, regulatory authorities and government bodies.
- Visibility of vendor's product with primary industry decision-makers.
- Increased brand awareness and visibility.

WHO SHOULD PARTNER

Reagents, coupling agents and raw materials	Lab equipment's	Flow reactors and other equipment's
Peptides for research, clinical trials, therapeutic manufacturing	Injectable supplies	CMO/CDMO
Peptide synthesis	CRO	Purification

KEY HIGHLIGHTS

- 9 hours of engaging content across 1 day
- 20+ Speakers
- Panel discussions, Roundtables and fire side chats
- 50+ Professionals under one roof
- Networking session

KEY TOPICS

- Navigating the Challenges of Bringing New Therapeutic Modalities to Market: A Deep Dive into Technical and Regulatory Considerations
- The Manufacturing Dilemma: Synthetic or Recombinant – Choosing the Right Path for Scalable and Cost-Effective Production
- From Bench to Approvals: Regulatory Complexities Peptides & Oligonucleotide Approvals
- Scaling Peptide Production: Overcoming Challenges from Grams to Kilograms
- Greener Peptide Manufacturing: Reducing Solvent Use and Managing Waste

SPEAKERS 2025

Dr. Ganesh Ramachandran
Head of Peptide Purification - R&D
Biocon

Shubhadeep Sinha
Senior Vice President,
Head - Clinical Development &
Medical Affairs (CD&MA)
Hetero

Satyajit Tillu
Technical Services Head-Peptides
Piramal Pharma

Dr. Tathagata Dutta
President
Jodas Expoim

Dr. Vadiraja Bhat
Sales Development Manager- Biopharma
Agilent Technologies India Pvt.Ltd.

Ranjan Chakrabarti
Biopharma Professional

Dr. Ashutosh Kumar
Professor - Department of Biosciences
and Bioengineering
IIT Bombay

Dr. Akhil Kumar
Chief Medical Officer
Aurigene Oncology

Shailendra Gaur
Director – Process Development
Aspergen Inc

Hosahudya N Gopi
Professor - Chemistry
IISER Pune

Darshan Aigal
Head Regulatory Affairs Complex Generics
and Biologics
Cipla Ltd.

Dr. Udaya Kiran Marelli
Principal Scientist- Central NMR Facility
CSIR - National Chemical Laboratory (NCL)

Amol Sonawane
Associate Director - Bio-Clinical Studies
Ferring Pharmaceuticals

Ashish Dwivedi
Principal Scientist & Lead- Peptides &
Complex Injectables
Alembic Pharmaceuticals Limited

Peptides Therapeutics Summit

11th November 2025

Hyderabad

Advancing Therapeutics Through Peptide Innovation - Transforming Medicine Molecule by Molecule

Tuesday, 11th November 2025

08:00 – 09:45	**Registration & Networking**
09:45 – 10:00	**Opening Remarks from Informa Markets in India**
10:00 – 10:15	**Keynote Session: Peptide Therapy on the Rise: Advancing Therapeutics in India** **Dr. Ganesh Ramachandran , Head of Peptide Purification -R&D, Biocon**
10:15 – 11:00	**Leadership Panel Discussion: Navigating the Challenges of Bringing New Therapeutic Modalities to Market: A Deep Dive into Technical and Regulatory Considerations** • Addressing issues like degradation, short half-life, and delivery route limitations • Regulatory landscape for current global guidelines, approvals, and data requirements • Ensuring consistency, purity, and cost-effectiveness in large-scale peptide synthesis and formulation • Accelerate clinical translation of novel peptide therapies maintaining compliance and quality **Moderated By:** **Dr Shubhadeep Sinha,** Senior VP, Head - Clinical Development & Medical Affairs (CD&MA), **Hetero** **Panellist:** **Dr.Akhil Kumar,** Chief Medical Officer**, Aurigene Oncology** **Dr.Tathagata Dutta,** President**, Jodas Expoim** **Ashish Dwivedi,** Principal Scientist & Lead- Peptides & Complex Injectables**, Alembic** **Amol Sonawane,** Associate Director - Bio-Clinical Studies**, Ferring Pharmaceuticals**
11:00 – 11:20	**Tools for Peptide Therapeutics: Separation and Characterization of GLP-1 and Novel Peptides** • Explore advanced LC and MS solutions for high-resolution separation and characterization of complex peptide mixtures, including GLP-1 analogs. • See how streamlined analytical workflows enhance quality, consistency, and regulatory compliance from discovery to manufacturing • Learn how Agilent's integrated technologies accelerate peptide analysis for scalable, next-generation therapeutic development **Dr. Vadiraja Bhat,** Sales Development Manager- Biopharma**, Agilent Technologies India Pvt.Ltd.**
11:20 – 11:50	**Networking Coffee Break**
11:50– 12:40	**Panel Discussion: The Manufacturing Dilemma: Synthetic or Recombinant – Choosing the Right Path for Scalable and Cost-Effective Production** • Evaluating cost, purity, yield, and complexity between synthetic and recombinant approaches

Peptides Therapeutics Summit

11th November 2025

Hyderabad

- Assessing which method better supports gram-to-kilogram scale-up
- Quality & Regulatory Impact: Understanding how each route aligns with GMP and regulatory expectations

Moderated By:
Dr. Ranjan Chakrabarti, Biopharma Professional

Panellist:
Shailendra Gaur, Director- Process Development, **Aspergen Inc**
Satyajit Tillu, Technical Services Head-Peptides, **Piramal Pharma**
Dr. Udaya Kiran Marelli, Principal Scientist**, CSIR-National Chemical Laboratory (NCL)**
Darshan Aigal, Head Regulatory Affairs Complex Generics & Biologics , **Cipla Ltd**

12:40 – 13:10 **Advanced Analytical tools for Assessing Peptide Characterization & Comparability**

- Sameness of peptide structure (Primary and HOS)
- Peptide aggregation
- Impurities and risk of immunogenicity

Ashish Dwivedi, Principal Scientist & Lead- Peptides & Complex Injectables**, Alembic**

13:10 – 13:40 **The Future of Targeted Therapy in India: Integrating CRISPR and Peptide Platforms**

- Explore how combining CRISPR with peptide-based delivery systems enhances therapeutic
- Discuss the potential for CRISPR-peptide integration to enable treatment for complex diseases like cancer, rare genetic disorders, and infectious diseases
- Examine the evolving regulatory frameworks and the need for R\&D infrastructure

Dr.Akhil Kumar, Chief Medical Officer**, Aurigene Oncology**

13:40 – 14:30 **Networking Lunch Break**

14:30 – 15:00 **NMR Spectroscopy, Spectral Signatures, Pattern Recognition for HOS based Biologics**

- Exposition of high-resolution NMR techniques and other orthogonal biophysical techniques to understand the HOS of Biopharmaceuticals in their formulated states
- Establishing the HOS of Biologics drugs and their quality assurance or control

Dr. Ashutosh Kumar, Professor - Department of Biosciences and Bioengineering**, IIT Bombay**

15:00 – 15:30 **Advances in Peptide Impurity Profiling**

Prof. Hosahudya N Gopi, Professor- Chemistry, **IISER, Pune**

15:30 – 16:00 **Greener Peptide Manufacturing: Reducing Solvent Use and Managing Waste**

- Environmental concerns in peptide production
- Sustainable waste management practices in peptide manufacturing
- Exploring eco-friendly alternatives to traditional peptide production methods

Satyajit Tillu, Technical Services Head-Peptides, **Piramal Pharma**

16:00 – 16:15 **Networking Coffee Break**

Peptides Therapeutics Summit

11th November 2025

Hyderabad

16:15 – 16:45	**Evolving Regulatory Expectations: From Small Molecules to Peptides to Biologics** **Darshan Aigal**, Head Regulatory Affairs Complex Generics & Biologics , **Cipla Ltd**
16:45 – 17:15	**Peptide Medicinal Chemistry: Designing Hybrid Scaffolds for Future Therapeutics** • Design of hybrid peptide scaffolds: Development of functionalised peptides incorporating heterocyclic and pharmacophoric motifs to enhance activity, stability, and diversity. • SPPS-compatible modification strategies: Optimisation and development of appropriate chemistry to access biologically active peptide conjugates. • Bridging discovery and therapeutics: Advancing peptide medicinal chemistry toward hybrid scaffolds that connect small-molecule design principles with peptide-based drug development. **Dr. Udaya Kiran Marelli,** Principal Scientist**, CSIR-National Chemical Laboratory (NCL)**

End of the Conference

EVENT PARTNERS

Silver Partner

Agilent
Trusted Answers

Exhibit Partners

eurofins | Bioanalytical Services

Waters™

DAICEL
Sustainable Value Together

Association Partner

C-CAMP
Centre for Cellular and Molecular Platforms

TICKET PRICING

Category	Fee (INR per person)
Standard	₹15,000

*Note: (Mandatory 18% GST will be applicable on all bookings.)

CONTACT US:

For Speaking Opportunities
Archana Shantharam
+91 93431 97703 | archana.shantharam@informa.com

For Delegate Registrations
Saleem Pasha
+91 99867 68672 | saleem.pasha@informa.com

Mili Shah
+91 99308 97361 | mili.shah@informa.com

For Sponsorship, Speaking and Exhibit opportunities
Prathamesh Kesarkar
+91 74992 52173 | prathmesh.kesarkar@informa.com

For Marketing Alliances
Shrushti Kamath
+91 91672 26207 | shrushti.kamath.IN@informa.com

informa markets

Informa Markets India Private Limited, 1st Floor B wing, Unit No 3 and 4, Solitaire XIV,
Guru Hargovindji Marg, Chakala, Andheri East, Mumbai Suburban, Maharashtra, 400093